When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. CorMedix just met that criteria with a new score of 83.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an RS Rating north of 80 as they begin their biggest price moves.
CorMedix is now considered extended and out of buy range after clearing a 6.39 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported 0% earnings growth in the latest quarterly report. Revenue rose 4,806%.
The company earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
